Browsing Tag
mavacamten
4 posts
Cytokinetics secures UK approval and NHS access for aficamten in obstructive HCM
UK approval and NICE reimbursement give aficamten access to 6,600 patients as Cytokinetics expands its global HCM commercial launch.
Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Bristol Myers Squibb’s Camzyos cleared a key adolescent Phase 3 hurdle in oHCM. Read what the SCOUT-HCM data could mean for growth and competition.
Bristol Myers Squibb completes $13.1bn acquisition of MyoKardia: A strategic move to strengthen cardiovascular portfolio
Bristol Myers Squibb has successfully completed its acquisition of MyoKardia, a clinical-stage biopharmaceutical company based in California. The…
Bristol Myers Squibb to acquire MyoKardia for $13.1bn: A strategic move to strengthen cardiovascular portfolio
Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has announced an agreement to acquire MyoKardia, a California-based…